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Abstract
Background: Although there have been many attempts to increase the therapeutic ratio of radiotherapy for gastric
mucosa-associated lymphoid tissue lymphoma (MALToma), only a few planning studies have reported the efficacy
of the modern radiotherapy technique till date. Therefore, we performed the dosimetric comparison among 3-
dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT) plans, using deep-
inspiration breath hold (DIBH) or free-breathing (FB) techniques, to determine the most optimal plan for gastric
MALToma.
Methods: We evaluated 9 patients with gastric MALToma for whom 3D-CRT, step-and-shoot IMRT (SIMRT),
volumetric-modulated arc therapy (VMAT), and tomotherapy plans with identical prescribed doses were generated
using DIBH or FB computed tomography (CT). Planning target volume (PTV) coverage and non-target doses were
calculated for each plan and compared with plan quality metric (PQM) scores.
Results: All 72 plans of 9 patients satisfied our dosimetric goals, and the IMRT plans and 3D-CRT plans had similarly
good conformity index values with no differences related to respiratory movement. IMRT plans yielded significantly
better doses to the organs-at-risk, and DIBH plans yielded significantly lower liver, heart, and lung Dmean and spinal
cord Dmax with smaller irradiated volumes compared to FB plans. For the mean PQM scores, VMAT-DIBH and SIMRT-
DIBH yielded the best scores, whereas 3D plans provided reduced beam monitor unit values.
Conclusion: Our findings demonstrate that modern RT technologies (DIBH with VMAT or SIMRT) could potentially
provide excellent target coverage for gastric MALToma while reducing doses to organs-at-risk. However, the
relevance of the most optimal plan considering clinical outcomes should be confirmed further in a larger patient
cohort.
Keywords: Mucosa-associated lymphoid tissue lymphoma, Radiotherapy, Planning study, Deep inspiration breath
hold, Intensity modulated radiotherapy
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: JINSUNG@yuhs.ac; YHI0225@yuhs.ac
†Seo Hee Choi and So Hyun Park contributed equally to this work.
1Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University
College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, South
Korea
Full list of author information is available at the end of the article
Choi et al. Radiation Oncology           (2019) 14:59 
https://doi.org/10.1186/s13014-019-1263-7
Background
Mucosa-associated lymphoid tissue lymphoma (MAL-
Toma) accounts for approximately 19% of all
non-Hodgkin lymphomas and can arise at any extrano-
dal site. In Korea, however, at least half of all MALTo-
mas present as primary gastric lymphomas [1, 2].
Several institutions have reported excellent disease con-
trol with radiation therapy alone, supporting the use of
modest doses in field radiotherapy (30–40 Gy) for pa-
tients with stage I–II gastric MALToma [3–8], although
systemic therapy may also be needed in cases involving
unsuccessful Helicobacter pylori eradication or H. pylor-
i-negative disease, depending on the disease stage.
The recent National Comprehensive Cancer Network
(NCCN) guidelines recommend 30 Gy involved-site radi-
ation therapy for gastric MALToma [9]; this generally
involves the entire stomach and adjacent perigastric
lymph nodes (if involved). Although this involved-site
radiation therapy uses low doses, the doses to the
organs-at-risk (OARs) near the stomach, such as the kid-
neys, small bowel, or liver, must be considered. To date,
several planning techniques involving anterior-posterior/
posterior-anterior fields (AP/PA) and 3-dimensional
conformal radiotherapy (3D-CRT) have been used to re-
duce radiation exposure to the OARs to within tolerance
limits, and intensity-modulated radiotherapy (IMRT)
techniques for gastric MALToma have recently been in-
troduced [10–15]. Despite the dosimetric advantages of
these modalities in terms of the doses to the OARs, con-
cerns regarding higher scattered doses have not been re-
solved [16]. Additionally, the effect of respiratory motion
on the accuracy of the treatment has raised concerns,
thus limiting the widespread use of IMRT.
Some institutions have implemented the deep-inspiration
breath hold (DIBH) technique to address these concerns.
However, only a few planning studies have included mod-
ern radiotherapy techniques when evaluating the efficacy of
this technique [11–13, 17]. Therefore, in the present study,
we performed a dosimetric comparison of 3D-CRT and
IMRT plans using DIBH or free-breathing (FB) techniques
to determine the most optimal treatment plan for gastric
MALToma. We additionally compared IMRT plans using
various techniques (step-and-shoot IMRT [SIMRT],
volumetric-modulated arc therapy [VMAT], and tomother-
apy) to identify the most dosimetrically optimal plan, using
the plan quality metric (PQM) to ensure an objective
assessment.
Materials and methods
Patient selection
Among 20 patients who received definitive radiotherapy
for gastric MALToma at our institution between 2016
and 2017, we selected only patients who underwent
computed tomography (CT) simulation scans using both
FB and DIBH, to make 4 different plans (3D CRT,
SIMRT, VMAT, and tomotherapy) per CT scan type (FB
or DIBH) of each patient. A total of 9 patients who re-
ceived definitive radiotherapy for localized gastric MAL-
Toma were selected consecutively for this planning
study. All cases were either H. pylori-positive but unre-
sponsive to H. pylori irradiation or H. pylori-negative.
Before the start of radiotherapy, each patient underwent
CT simulation scans (Aquilion LB; Toshiba Medical
System, Tokyo, Japan) using both FB and DIBH, per our
institutional protocol after at least 4 h of fasting. The pa-
tients received intravenous contrast agents and were
immobilized in a supine position with both arms raised
above the head. The range for CT scan was determined
to include all the OARs (such as the lungs, heart, kid-
neys, and bowel) that should be considered in planning.
In our institution, patients were scanned from approxi-
mately the level of the 7th thoracic vertebral body infer-
iorly to the level of the 4th lumbar vertebral body. Care
was taken to include the base of the heart and both kid-
neys. DIBH CT scans were performed while the patient
held his/her breath using the abdomen and chest motion
self-control (Abches) system, as described in our previ-
ous report [18].
In all patients, the gross tumor volume (GTV) was de-
fined as the whole stomach. However, different clinical
target volumes (CTVs) were set for FB and DIBH CT, as
the former must incorporate the concept of an internal
target volume (ITV) to account for respiratory move-
ment during treatment. The CTV was defined as the
GTV plus a 1.5-cm margin for FB CT, and GTV plus a
1.0-cm margin for DIBH CT. To account for set-up er-
rors, the planning target volume (PTV) was defined as
the CTV plus a 0.5-cm margin for all CT scans. For all
plans, the prescribed dose was equal to 30 Gy in 20
fractions.
Four different plans, including one 3D-CRT plan and
three IMRT plans (SIMRT, VMAT, and tomotherapy),
were generated per CT scan type (FB or DIBH) to yield
8 plans per case. Therefore, we compared 72 plans for 9
patients based on the planning modality and respiration
control methods. This study was approved by the insti-
tutional review board (IRB) of the Yonsei University
Health System (4–2017-1035).
Planning techniques
The FB and DIBH CT images and all datasets were
transferred to treatment planning systems. The 3D-CRT,
SIMRT, and VMAT plans were created with the RaySta-
tion (RayStation 5.0; RaySearch Laboratories, Stockholm,
Sweden), and tomotherapy plans were generated with a
TomoTherapy Hi-Art System (Accuray Inc., Madison,
WI, USA). The 3D-CRT plans comprised four 10-MV
energy beams, arranged as anterior-posterior opposed
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beams and two lateral beams. The SIMRT plans were
created using 7 angles (0°, 50°, 100°, 150°, 210°, 260°, and
315°) and a collimator angle of 90°, according to clinical
experience. The VMAT plans used 2 full 6-MV arcs. The
tomotherapy plans comprised helical beams optimized
using a field width of 1.05°, modulation factor of 2.4, and
pitch of 0.3. Each plan aimed to ensure 95% coverage of
the PTV to the prescribed dose, with critical organ dose
limits of 12.5 Gy and 10.0 Gy for the mean doses (Dmean)
to the liver and kidneys, respectively.
Dosimetric parameters for plan evaluation
A radiation oncologist following the Radiation Therapy
Oncology Group (RTOG) contouring atlases defined each
OAR contour. Each OAR contour was contoured, and the
body contour was automatically segmented using the
“Whole Body” contouring tool with the MIM software
(Cleveland, Ohio) in all patients. The dose distributions
for each plan were analyzed using dose-volume
histograms and dose distributions, and doses to the OARs
were evaluated using the following criteria:
1) Dmean to each kidney, liver, and heart
2) Maximum dose (Dmax) to the bowel and spinal cord
3) Dmean to both lungs, volume of both lungs receiving
≥5 Gy (V5), and volume of both lungs receiving
≥20 Gy (V20)
The PTV doses were evaluated using the following pa-
rameters to evaluate target coverage and homogeneity:
1) Percent volume of the PTV receiving at least 95%
of the prescription dose (TV95)
2) Homogeneity index (HI): HI = D5/D95
Where D5 and D95 represent the minimum doses to 5
and 95% of the PTV, respectively [19].
3) Conformity index (CI): CI = BV95/PTV
Table 1 Quality scores for each objective
Target Organ-at-risk (OAR)
Score PTV Rt. kidney Lt. kidney Spinal cord Liver Heart Lung Bowela
D95 (cGy) HI CI Dmean (cGy) Dmean (cGy) Dmax (cGy) Dmean (cGy) Dmean (cGy) Dmean (cGy) V20 (cm
3) Dmax (cGy)
0 < 2550 1.0 – > 1800 > 1800 > 3000 ≥2000 > 1000 ≥900 > 2000
1 2550 0.9 < 0.2, > 1.8 1800 1800 3000 1950 1000 950 2000
2 2600 0.8 0.2, 1.8 1700 1700 2900 1900 950 900 1900
3 2650 0.7 0.3, 1.7 1600 1600 2800 1850 900 850 1800
4 2700 0.6 0.4, 1.6 1500 1500 2700 1800 850 800 1700
5 2750 0.5 0.5, 1.5 1400 1400 2600 1750 800 750 1600
6 2800 0.4 0.6, 1.4 1300 1300 2500 1700 750 700 1500 2700
7 2850 0.3 0.7, 1.3 1200 1200 2400 1650 700 650 1400 2750
8 2900 0.2 0.8, 1.2 1100 1100 2300 1600 650 600 1300 2800
9 2950 0.1 0.9, 1.1 1000 1000 2200 1550 600 550 1200 2850–2950
3050–3150
10 3000 0.0 1.0 950 950 2100 1500 550 500 1100 3000
11 900 900 2000 1450 500 450 1000
12 850 850 1900 1400 450 400 900
13 800 800 1800 1350 400 350 800
14 750 750 1700 1300 350 300 700
15 700 700 1600 1250 300 250 600
16 650 650 1500 1200 250 200 500
17 600 600 1400 1150 200 150 400
18 550 550 1300 1100 150 100 300
19 500 500 1200 1050 100 200
20 400 400 1100 1000 50 100
The sum of scores for each objective is defined as the “raw plan quality metric (PQM)”. The maximum score was set to 178, and the PQM (%) was determined as
the percent of the Raw PQM to Max PQM for each plan
aBowel scoring was conducted differently because part of the bowel is included in the PTV, and therefore, the bowel dose partly reflects the PTV coverage
Abbreviations: PTV planning target volume, HI homogeneity index, CI conformity index
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Where BV95 represents the volume of the body receiv-
ing 95% of the prescribed dose [20].
In our practice, we used a radiotherapy plan analysis
program (Plan IQ™, Sun Nuclear co, Melbourne, FL,
USA) to generate scores for these dosimetric goals ac-
cording to the PQM. The scores were based on the con-
straints and dose-volume histograms of the planning
results and assigned to each evaluation object according
to the calculated dose [21, 22]. The quality scores for
each objective are shown in Table 1. The PQM (%) rep-
resents the ratio of the raw PQM to the maximum
PQM. The raw PQM is the evaluation score of each
treatment plan in the score template. The maximum
PQM is the highest score that the treatment plan can
achieve and is the sum of the highest scores for each ob-
jective set by the user of plan IQ (set to 178). By using
plan IQ, it is possible to create the score template for
each objective that users want to evaluate. Depending on
the treatment sites and prescribed dose, it is rated at a
higher score compared to other scores for significant ob-
jectives. Because higher scores can be assigned to im-
portant OARs, dosimetric weighting is determined by
clinical importance. To explain the score template, the
score template for the kidney and lung Dmean (Gy) is
shown in Additional file 1: Figure S1.
Statistical analysis
The Wilcoxon signed-rank test and Friedman test were
used for the group-wise statistical comparison of the 8
planning techniques (3D-DIBH, 3D-FB, SIMRT-DIBH,
SIMRT-FB, VMAT-DIBH, VMAT-FB, Tomo-DIBH, and
Tomo-FB). A p-value of < 0.05 was considered statistically
significant. Statistical analyses were performed using SPSS
software (Ver. 23.0; SPSS Inc., Chicago, IL, USA).
Results
Target coverage, conformity, and homogeneity
All plans satisfied the criteria for good PTV coverage,
conformity, and homogeneity. Accordingly, the
group-wise comparison of PTV dose distribution in-
volved the TV95 and D95 values of the 8 techniques.
Although all D95 values were larger than 95% of the
prescribed dose, the tomotherapy plans yielded the
best result, followed by SIMRT, VMAT, and 3D-plans,
with no differences between the DIBH and FB plans.
Statistically, the IMRT plans were significantly better
than 3D-CRT plans, SIMRT plans were significantly
better than VMAT plans, and tomotherapy plans were
significantly better than SIMRT plans. The mean D95
values of the 3D-DIBH, 3D-FB, SIMRT-DIBH,
SIMRT-FB, VMAT-DIBH, VMAT-FB, Tomo-DIBH,
and Tomo-FB plans are shown in Table 2 and Fig. 1(a)
(p < 0.001). The detailed results of statistical analyses
are presented in Additional file 2: Supplementary text
1.
Regarding the TV95, significantly larger irradiated vol-
umes were observed with FB plans than with DIBH
plans (mean: 1721 cc for FB > 1372 cc for DIBH, p <
0.001), indicating the need to compensate for respiratory
movement. The mean TV95 values of the 3D-DIBH,
3D-FB, SIMRT-DIBH, SIMRT-FB, VMAT-DIBH,
VMAT-FB, Tomo-DIBH, and Tomo-FB plans are shown
in Table 2 and Fig. 1(b) (p < 0.001). On statistical ana-
lyses, 3D plans yielded significantly higher TV95 values
than IMRT plans, whereas VMAT plans had the lowest
TV95 when plans using the same respiration modality
were compared. The results of statistical analyses are
presented in Additional file 2: Supplementary text 2.
Regarding homogeneity, the 3D, SIMRT, and VMAT
plans yielded similar HI values, regardless of respiratory
movement. Although plans showed favorable homogen-
eity, the tomotherapy plans were the most superior, re-
gardless of respiratory movement. The mean HI values
of the 3D-DIBH, 3D-FB, SIMRT-DIBH, SIMRT-FB,
VMAT-DIBH, VMAT-FB, Tomo-DIBH, and Tomo-FB
plans are shown in Table 2 and Fig. 1(c) (p < 0.001). The
detailed results of statistical analyses are presented in
Additional file 2: Supplementary text 3.
Regarding dose conformity, the 3D plans yielded the
worst CI values, followed by IMRT plans (which had
similar CI values). Among the IMRT plans, SIMRT and
VMAT yielded the best CI values. As shown in Fig. 2,
which demonstrates the isodose lines, 3D-DIBH and
3D-FB were the least conformal plans, followed by
Tomo-DIBH and Tomo-FB. No differences were
observed according to respiratory movement. The mean
CI values of the 3D-DIBH, 3D-FB, SIMRT-DIBH,
SIMRT-FB, VMAT-DIBH, VMAT-FB, Tomo-DIBH, and
Tomo-FB plans are shown in Table 2 and Fig. 1(d) (p <
0.001). The detailed results of statistical analyses are pre-
sented in Additional file 2: Supplementary text 4, and
differences in homogeneity and conformity among the
plans are demonstrated in an example of the plans with
isodose lines (Fig. 2).
OAR doses
The DIBH plans, which involved smaller irradiated
volumes, yielded lower kidney Dmean values on both
sides relative to the FB plans. The Dmean values were
the highest for the 3D-CRT plans, followed by
tomotherapy, SIMRT, and VMAT, although these dif-
ferences were not significant. Similarly, the DIBH
plans yielded significantly lower Dmean values for the
liver, heart, and lungs, compared to FB plans. For
these OARs, the VMAT-DIBH and SIMRT-DIBH
plans were significantly superior to the others,
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whereas the Tomo-FB and 3D-FB plans yielded the
worst outcomes. As shown in Fig. 2, the DIBH plans
yielded smaller irradiated volumes for the liver and
kidneys, compared to the corresponding FB plans.
For the spinal cord, DIBH plans yielded significantly
lower Dmax values, compared to FB plans. 3D-CRT plans
yielded the highest values, followed by tomotherapy,
SIMRT and VMAT plans. The values and results of stat-
istical analyses are presented in Fig. 1(e) and Additional
file 2: Supplementary text 5. In contrast, the Dmax values
for the small bowel did not differ significantly among
the plans (Fig. 1(f )), although the SIMRT plans and
VMAT plans yielded the highest values, followed by the
3D plans and Tomo plans. Respiratory movement also
had no effect on the small bowel Dmax values. The
results of statistical analyses are presented in Additional
file 2: Supplementary text 6, and the mean values for
each OAR with each plan are shown in Table 2.
PQM
As shown in Table 1, the PQM score (%) of each plan
was determined after weighting each dosimetric factor
according to clinical importance. The VMAT-DIBH plan
and SIMRT-DIBH plan acquired the best mean PQM
scores (%) of 76.8 and 75.6, respectively. The VMAT-FB,
Tomo-DIBH, SIMRT-FB, and Tomo-FB plans acquired
mean PQM scores of 69.3, 69.2, 66.6, and 62.1, respect-
ively. Both 3D-DIBH and FB plans acquired the lowest
PQM scores (%) of 60.6 and 50.9, respectively (Table 2).
All DIBH plans yielded significantly superior PQM
Fig. 1 Boxplots of (a) the doses to 95% of the PTV (D95), (b) percent volume of the PTV receiving at least 95% of the prescription dose (TV95),
(c) homogeneity index (HI), (d) conformity index (CI), (e) Dmax of the spinal cord, and (f) Dmax of the small bowel of the 8 different plan groups. *The
significant differences between groups are shown in the Supplementary text
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Fig. 2 Treatment plans for 1 patient; (a) isodose lines in the image showing the curvature of the stomach, (b) isodose lines in the image showing
the irradiation dose to both the kidneys. In Fig. 2(a), the difference in D95, TV95, HI, and CI values among treatment plans can be compared
visually to some extent. In Fig. 2(b), the difference between the right and left kidney Dmean, liver Dmean, and bowel Dmax doses among treatment
plans can be compared visually to some extent
Fig. 3 Boxplots of (a) plan quality metric (PQM) scores and (b) motor units (MU) of the 8 different plan groups. DIBH, deep-inspiration breath hold; FB, free-
breathing; 3D, 3-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; VMAT, volumetric-modulated arc therapy; Tomo, tomotherapy
Choi et al. Radiation Oncology           (2019) 14:59 Page 7 of 12
scores to the corresponding FB plans (Fig. 3(a)).
Although VMAT-DIBH and SIMRT-DIBH were signifi-
cantly better than most other plans, these two plans
were not significantly different (p = 0.066). The
VMAT-FB and SIMRT-FB plans were significantly better
than 3D-CRT plans (DIBH or FB), but significantly
worse than those obtained using the DIBH technique
(VMAT-DIBH or SIMRT-DIBH). When we further
scored the plans by summing all items at a 1:1 ratio (not
weighting each dosimetric factor according to clinical
importance), the same plan quality rankings as PQM
(weighting each dosimetric factor by users according to
clinical importance) were achieved. As shown in Table 3,
the VMAT-DIBH, SIMRT-DIBH, and Tomo-DIBH plans
yielded the best results, and all were superior to the cor-
responding FB plans. The 3D-DIBH and 3D-FB plans
yielded the most inferior scores for almost all factors.
Motor unit and clinical meaning
The IMRT plans yielded significantly higher monitor
unit (MU) values, whereas the 3D-CRT plans yielded
significantly lower MU values relative to the other mo-
dalities. Although the VMAT and SIMRT plans did not
yield significantly different MU values, all were signifi-
cantly lower than those of tomotherapy plans. The
Tomo-DIBH and Tomo-FB plans required substantially
high mean MU values (7567 and 7566, respectively;
Table 2), and the MU values did not significantly differ
between the DIBH and corresponding FB plans (Fig.
3(b)).
We note that when performing actual treatments
using the DIBH technique, beam irradiation can be per-
formed only when the patient is holding his/her breath
(intervals of ~ 15 to 20 s). As free breathing must be
allowed between the periods of breath holding, the total
treatment time in an actual clinic setting may be longer
than expected. In addition, patient training time, DIBH
device set-up time, and accurate monitoring in the treat-
ment room are required. Therefore, the time required
for actual treatment could be significantly increased if
the IMRT and DIBH techniques are combined.
Discussion
In this study, modern radiotherapy plans combining
IMRT and DIBH (VMAT-DIBH, SIMRT-DIBH) were
found to be significantly superior to 3D plans for gastric
MALToma. We further observed that tomotherapy plans
had exceptionally high MU values and yielded no not-
able benefits in this context. Although it remains unclear
whether DIBH or IMRT is more useful in a clinical set-
ting, VMAT-FB seems to yield better dosimetric out-
comes when compared to 3D-DIBH. One of the
strengths of this study is that we performed a dosimetric
comparison among various modern radiotherapy tech-
niques combining DIBH and IMRT and suggested the
most appropriate treatment combination strategy re-
garding target coverage, OAR doses, and comprehensive
evaluation for gastric MALToma.
Since the Memorial Sloan-Kettering Cancer Center
(MSKCC) first described the treatment of gastric MAL-
Toma with RT alone [3], subsequent studies have shown
favorable results in various populations, including pa-
tients with H. pylori-independent disease [4–8]. How-
ever, significant variations in stomach size and shape,
digestive movement, and respiratory motion are known
to cause uncertainty during the simulation and delivery
of treatment to the stomach, and a safe, efficient irradi-
ation technique that can optimally overcome these un-
certainties with adequate margins has not been well
established. The simplest approach to this issue involves
Table 3 The ranking of each dosimetric variable (mean value) and scores generated by summing all rankings of the 8 plans
Variables 3D-DIBH 3D-FB sIMRT-DIBH sIMRT-FB VMAT-DIBH VMAT-FB Tomo-DIBH Tomo-FB
TV95 7 8 3 5 1 4 2 6
D95 7 4 3 4 6 5 2 1
HI 7 4 3 5 6 8 1 2
CI 8 7 4 3 2 1 6 5
Kidney Dmean 7 8 3 5 1 4 2 6
Spinal cord Dmax 8 6 2 4 1 3 5 7
Liver Dmean 5 8 2 4 1 3 6 7
Heart Dmean 4 8 2 6 1 5 3 7
Lung Dmean 3 8 2 6 1 4 5 7
Bowel Dmax 3 4 7 8 6 5 1 2
MU 2 1 5 6 3 4 8 7
Sum 61 66 36 56 29 46 41 57
Abbreviations: DIBH deep-inspiration breath hold, FB free-breathing, IMRT intensity-modulated radiotherapy, VMAT volumetric-modulated arc therapy, TV the
volume of the body receiving 95% of the prescribed dose, HI homogeneity index, CI conformity index, MU motor unit
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the addition of an adequate margin to the CTV. Previ-
ous studies of RT planning techniques for gastric lymph-
oma have recommended a PTV comprising the CTV
plus a 1.5–2-cm margin in all directions [10, 12] for the
delivery of radiation in a FB state. Other studies have
used respiratory synchronized 4D-CT images to provide
information about respiratory-induced organ motion
during treatment planning and minimize motion uncer-
tainties [13, 23]. Specifically, Matoma et al. [17] com-
pared the usefulness of 4D-CT vs. a uniform margin for
the treatment planning of gastric MALToma, and found
that the former yielded a significantly smaller mean PTV
volume, with significantly lower mean doses to the liver
and heart. According to the International Lymphoma
Radiation Oncology Group (ILROG) guidelines for the
CTV [24], the entire stomach should be considered to
harbor disease even if the tumor appears confined to
one area, and abnormal or suggestive perigastric lymph
nodes can be included in the CTV. Respiratory
motion-induced changes in stomach position should be
detected using 4D-CT simulation or fluoroscopy when
determining the ITV, and an additional margin of
approximately 1 cm is often added to the CTV for this
purpose. The PTV (normally ~ 1 cm) should account for
setup variations. Moreover, radiotherapy planning based
on 4D-positron-emission tomography (PET)-CT/4D-CT
together with online cone-beam CT might be helpful to
define PTV margins used for optimizing individual tar-
get coverage and estimating interfractional or intrafrac-
tional gastric movement [25].
DIBH has become a standard cardiac-sparing tech-
nique during the treatment of left-sided breast cancer
[26–29], and several experts in lymphoma treatment
centers have recently reported the use of DIBH for me-
diastinal lymphoma [30–33]. In most patients, DIBH
reduces heart and lung doses by elongating the heart,
resulting in greater separation from the target volume
and increasing the lung volume. In DIBH, smaller PTV
margins could be applied to further accentuate the
organ-sparing benefit. Therefore, this respiratory tech-
nique is being considered for use during the treatment
of other organs (i.e., liver and stomach) at various spe-
cialized institutions, including ours. More recently,
Wang et al. demonstrated that there could exist substan-
tial interfractional variation in stomach volume despite
treatment with breath-hold and restriction of oral intake,
and daily CT image guidance RT (CT-IGRT), in combin-
ation with a DIBH, enabled better target coverage with
even smaller PTV margins (0.5–1.0 cm) while treating
gastric MALToma [34].
Several investigators have also described the use of
IMRT for the treatment of mediastinal lymphoma [32,
35, 36]. As expected, IMRT improves target conformity
and reduces OAR doses. However, this technique also
increases the volume of low-dose exposure in tissues
such as the lungs, heart, and breasts. Notably, the use of
the IMRT or DIBH technique in the treatment of Hodg-
kin lymphoma results in better protection of the heart
and lungs [30, 31, 37]. Therefore, the combination of
IMRT and DIBH would be expected to further reduce
the doses to the OARs. In addition to the information
on the breath-hold technique included in the ILROG
guidelines [38], more number of clinical attempts is
ongoing to combine IMRT and DIBH effectively for
Hodgkin lymphoma.
In contrast to the situation with Hodgkin lymphoma,
only a few studies have evaluated the use of modern
radiotherapy techniques for gastric MALToma. In the
first planning study for gastric MALToma, conducted by
the MSKCC to determine the most advantageous tech-
nique [10], the PTV was defined as the CTV plus a
2-cm margin to account for respiratory-induced move-
ment of the stomach during FB. In a comparison of AP/
PA, 3D-CRT, and IMRT plans, 4-field 3D-CRT markedly
decreased the dose to the kidneys when this organ over-
lapped with the PTV, and the findings with IMRT plans
suggested that the kidney and liver doses could be incre-
mentally improved in selected patients. Two relevant
studies were also reported by Korean researchers. Lim et
al. [12] retrospectively compared 2 different planning
techniques (2D and 3D-CRT) for gastric MALToma
based on CT with a FB status; the PTV was defined as
the CTV plus a 1–1.5-cm margin, and an additional
1-cm margin was added in the craniocaudal direction to
compensate for respiratory-induced stomach motion.
For 3D-CRT plans, AP/PA or 3–4 non-coplanar fields
were used according to the physician’s preference.
Although that retrospective study compared treatment
outcomes rather than dosimetric planning, the 3D-CRT
plans yielded significantly better PTV coverage, con-
formity, and kidney doses on both sides when compared
to 2D-RT plans, without compromising the oncologic
outcomes. Furthermore, Bae at al. [13] compared 5
planning techniques (AP/PA, 4-field, 3D-CRT, IMRT
with only coplanar beams, and IMRT with a few
non-coplanar beams). 4D-CT was conducted under a FB
status, ITV was defined as the sum total of the entire
stomach at every respiratory stage, and CTV was defined
as the ITV plus a 1-cm margin. The authors observed
the highest mean kidney and liver doses with the AP/PA
plan and a 4-field plan, respectively. As observed in our
study, Bae and colleagues observed better conformity
and hepatic toxicity with IMRT plans, but found no
significant difference between the coplanar and
non-coplanar IMRT plans. Unlike our study, however,
these previous studies were limited by a lack of compari-
son with the DIBH technique and with more recent
IMRT plans (e.g., VMAT and tomotherapy). In our
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institution, we defined CTVs as the GTV plus a 1.5-cm
margin for FB plans, and GTV plus a 1.0-cm margin for
DIBH plans, without 4D-CT scans. There was only a
small difference in CTV margins compared to that in
other planning studies. Moreover, considering that this
study was a dosimetric study for comparing optimal
radiotherapy planning techniques in patients, the con-
clusion would not change and this seems reasonable
compared to other studies.
Similar planning studies have been conducted abroad,
although neither modern DIBH nor various IMRT plan-
ning techniques have been evaluated. A similar planning
study that compared four-field 3D-CRT, half-field RT,
and IMRT was performed by Japanese researchers [11].
In that study, planning CT was performed during shal-
low exhale and inhale phases; the CTVs from both
phases were fused, peristalsis margins were added to ob-
tain the ITV, and the PTV was generated by expanding
the ITV by 1 cm in all directions. The IMRT and
half-beam methods were found to reduce the doses to
the kidneys and liver, compared to 3D-CRT. In a retro-
spective Chinese study [23], the dosimetric superiority
and efficacy, toxicity, and quality of life were investigated
in patients with gastric diffuse large B-cell lymphoma
who received IMRT. IMRT was performed with a FB
status, and the PTV was defined as the CTV plus 1–2
cm in all directions. The 5-year overall survival,
progression-free survival, and locoregional control rates
were 80, 75, and 93%, respectively, with excellent target
coverage and long-term global and functional quality of
life scores.
The application of DIBH to gastric lymphoma might
differ significantly with respect to the dose and target lo-
cation. The use of DIBH requires 10–20min of coaching
during the treatment simulation and prior to administra-
tion of the first fraction. A patient is expected to hold
their breath for 10–20 s per respiratory cycle, during
which radiation must be delivered. This limitation pro-
longs the daily treatment time by a few minutes, and the
addition of IMRT can further affect the treatment time.
Additionally, each treatment requires a very sophisti-
cated protocol. However, patients with gastric lymphoma
account for only a small proportion of departmental
workloads, and therefore, these limitations may be out-
weighed by the improved treatment accuracy and reduc-
tion in late adverse events.
This study had a few limitations. First, the relatively
small sample size might have limited our ability to make
firm recommendations regarding the usefulness of
DIBH. Second, as this was a treatment planning study,
we could not demonstrate the oncologic outcomes or
prevalence of secondary malignancies after long-term
follow-up in the same cohort. Still, we note that almost
2 years have passed since our institution actually used
this technique, and no treatment failures have been
reported, although a long follow-up duration would be
needed given the late disease recurrence of this disease
entity. Third, the plan IQ-based scoring method only
calculates the target and OAR doses using CT density,
but does not consider the delivery modality. In fact, no
precise radiotherapy plan scoring system uses subjective
criteria to evaluate each objective item. In other words,
it would not be possible to define an absolute score for
each treatment plan, although relative comparisons
among different plans are possible. Our results should
be interpreted in consideration of the aforementioned
points, and they need to be verified through further clin-
ical studies.
Conclusions
Our findings demonstrate that modern radiotherapy
plans combining DIBH with VMAT or SIMRT were sig-
nificantly more beneficial than 3D plans for gastric
MALToma by saving the OARs and enhancing conform-
ity, regardless of concerns about increased MUs. Al-
though whether DIBH, VMAT, or SIMRT is more useful
in the clinical setting is unclear, VMAT-FB seems to be
better than 3D-DIBH regardless of target margins. Fur-
ther studies are needed to confirm the relevance of the
most practical plan considering clinical outcomes.
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